A clinical trial to study the affect of allopurinol compared with placebo in patients of CKD

"Allopurinol for CVD in CKD:A double blind randomized controlled trial"

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/033018

Enrollment

113

Registered

2021-04-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified Health Condition 2: N189- Chronic kidney disease, unspecified

Interventions

Intervention1: Allopurinol: Allopurinol will be compared with placebo in Ckd patients meeting inclusion criteria and outcome would be seen for primary and secondary outcome Control Intervention1: ALLO

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age 18-75 years 2.eGFR by CKD-EPI 10-45 ml/min/1.73m2 3.Serum uric acid >_6mg/dl 4.Clinically stable for last 3 months as judged by treating physician

Exclusion criteria

Exclusion criteria: 1.Receiving Long term hemodialysis 2.Receiving immunosuppression therapy 3.Diagnosis of Gout 4.Diagnosis of CLD 5.Diagnosis of malignancy 6.Having received hypouricemic therapy in last 30 days 7.History of allergy to allopurinol

Design outcomes

Primary

Measure	Time frame
Composite of MACE(major adverse cardiovascular outcomes),CAD,PVD,CVA,any coronary or peripheral revascularization procedure and death due to CVD.Timepoint: outcomes would be assessed at 3,6,9 and 12 months	—

Secondary

Measure	Time frame
Need for RRT,composite of 50% decline in GFR and need for RRT,change in eGFRTimepoint: 6 and 12 months	—

Countries

India

Contacts

Public ContactTejasvi

IPGMER and SSKM Hospital

deepsircar@gmail.com9433407355

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026